NCT06441227View on ClinicalTrials.gov

Safety and Tolerance of Increased Doses of HRS-5346 Tablets in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

June 13, 2024

Primary Completion Date

January 9, 2025

Study Completion Date

January 9, 2025

Conditions
Lipoprotein Disorder Disease
Interventions
DRUG

HRS-5346 tablets

Part 1: single dose. Part 2: single dose with food effects. Part 3: single dose multiple doses.

DRUG

placebo

Part 1: single dose. Part 2: single dose with food effects. Part 3: single dose multiple doses.

Trial Locations (1)

215008

The First Affiliated Hospital of Suzhou University, Suzhou

All Listed Sponsors
lead

Shandong Suncadia Medicine Co., Ltd.

INDUSTRY

NCT06441227 - Safety and Tolerance of Increased Doses of HRS-5346 Tablets in Healthy Subjects | Biotech Hunter | Biotech Hunter